MKGAY News and Press, Merck KGaA ADR From 03/30/19

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more ...

Deals and Financings Tianjin CanSino Biologics, a vaccine company, expects to raise up to $160.5 million in a Hong Kong IPO, which will begin trading on March 28. The company is developing 15 vaccine candidates for 12 disease areas. Its Ebola vaccine has been approved for use, and the comp...

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. AbbVie And Roche Have Trouble With Venclexta As Partial Clinical Hold Is Placed News: Recently, AbbVie ( ABBV ) and Roche ( RHHBY ) announced tha...

This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited . We analyze the attractiveness and profitability of each spread going forward and indicate the trading position ...

Merck KGaA ( OTCPK:MKGAY ) will collaborate with French outfit Iktos , leveraging the latter's generative modeling artificial intelligence (AI) technology in drug discovery and design. More news on: Merck KGaA ADR, Healthcare stocks news, Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Time to look ahead after the market came off its best two-month run in years. The e...

Merck KGaA ( MKGAF ) (MKGAY) and GlaxoSmithKline ( GSK ) announced a global collaboration to jointly develop and commercialize M7824, a TGF-beta. As per the terms of the agreement, Merck KGaA will receive 300M Euros, in the form of an upfront payment, 500M Euros, contingent on clinical success...

Merck KGaA ( OTCPK:MKGAY ) inks a collaboration deal with GlaxoSmithKline (NYSE: GSK ) to jointly develop and commercialize M7824, a bifunctional fusion protein, for treatment-resistant cancers. More news on: Merck KGaA ADR, GlaxoSmithKline, Merck & Co Inc., Healthcare stocks news, S...

Merck KGaA ( OTCPK:MKGAY ) out-licenses exclusive rights to two DNA-dependent protein kinase (DNA-PK) inhibitors, M981 (formerly VX-984) and a preclinical candidate, to Vertex Pharmaceuticals ( VRTX -0.8% ) for gene-editing applications in six inherited diseases. The company says DNA-PK ...